USDAnalytics announces its latest study, “Nuclear Medicine Equipment Market, 2025–2034,” revealing a market poised to rise from $6.8 billion in 2025 to $10.2 billion by 2034 (4.6% CAGR). Momentum stems from next-gen PET/CT and SPECT/CT, expanding theranostic pathways, and investments that secure radioisotope availability. Recent moves—Hermes’ CE-marked SIRT planning suite, Siemens Healthineers’ acquisition of AAA’s molecular imaging business, Curium’s regional build-out, and new alpha-isotope supply agreements—underscore a rapidly modernizing ecosystem.
Key Findings:
- PET accelerates; SPECT leads today: SPECT systems account for 40.1% share (2025) on broad cardiac use and cost efficiency, while PET systems post the fastest growth (5.8% CAGR) on oncology staging, long-AFOV platforms, and expanding tracers.
- Oncology is the demand engine: Oncology represents 44.5% of applications (2025) and is the fastest-growing area (5.5% CAGR) as precision medicine and theranostics become standard of care.
- Isotope sovereignty rises: Partnerships and supply deals (e.g., Ac-225 and F-18 pipelines) plus site-level production capacity reduce shortages and enable same-day therapy planning.
- Software and AI move the needle: Vendor-neutral dosimetry, automated reconstruction, and FDA/CE-cleared deep-learning algorithms improve image quality, lower dose, shorten scans, and lift throughput—key ROI drivers for providers.
Growth Drivers & Opportunities
Hospitals are adopting compact cyclotrons to locally produce alpha/beta emitters (e.g., Ac-225) that power PSMA and NET therapies. Concurrently, AI-assisted reconstruction, automated positioning, and vendor-neutral dosimetry elevate image fidelity and consistency, enabling lower radiation dose and faster scans while standardizing care across sites.
Decentralized microreactors and alternative Mo-99 production methods tackle chronic isotope shortages, cutting logistics risk and costs. By localizing Tc-99m supply, imaging centers stabilize scheduling, expand service lines, and improve economics—creating a step-change in utilization and uptime for SPECT/CT fleets.
Leading Players
Global leaders are converging on hybrid imaging, theranostics-ready platforms, and AI-enabled software. Siemens Healthineers advances long-AFOV PET/CT and oncology workflows; GE HealthCare scales CZT SPECT/CT and deep-learning reconstruction; Philips pushes fully digital PET and enterprise imaging interoperability; Canon Medical emphasizes mobile TOF PET-CT and workflow automation; United Imaging Healthcare expands total-body PET and AI suites to democratize precision imaging. Radiopharma specialists and supply-chain partners deepen ties with OEMs to align hardware, tracers, and dosimetry into integrated, outcome-driven offerings.
Market Segmentation & Share Insights
- By Product: SPECT systems 40.1% share (2025); PET systems fastest growth at 5.8% CAGR. Planar gamma cameras persist in basic imaging; cyclotrons gain relevance for on-site isotope production.
- By Application: Oncology 44.5% share (2025) and 5.5% CAGR; cardiology remains material via myocardial perfusion (SPECT); neurology expands with amyloid/tau PET and DAT imaging.
- By End User: Hospitals lead installed base; diagnostic centers grow with PET/CT upgrades; academic/research sites anchor total-body PET and theranostic trials.
Global Hotspots
The United States leads in theranostics adoption, AI approvals, and PET/CT upgrades. Germany scales radiopharmaceuticals post-acquisitions and advances AI reconstruction. Canada installs long-AFOV PET/CT to boost research and throughput. Japan prioritizes high-resolution PET and hybrid R&D. The UK expands cardiac SPECT/PET and home-grown imaging software. China accelerates domestic PET/SPECT production and AI devices. India benefits from “Make in India” and new nuclear medicine departments. Switzerland democratizes access with ultra-compact brain PET.
Unlock full report insights now: Nuclear Medicine Equipment Market
The report findings are based on primary interviews with OEMs, radiopharmacies, and providers; analysis of regulatory filings, clinical literature, and company disclosures; and bottom-up modeling by product, application, end user, and region for 2025–2034.
Media Contact:
Harry James
Sales Manager
USD Analytics
+1 213-510-3499
###